Brielle Benyon

The efficacy and safety of naratuximab emtansine plus rituximab appear impressive for patients with B-cell non-Hodgkin lymphomas who are ineligible for stem cell transplant or chimeric antigen receptor T-cell therapy.

In patients with cancer, anxiety and depression can influence how they view cancer clinical trials, which leads to low enrollment.

Progression-free survival after [vic]-trastuzumab duocarmazine treatment in patients with pretreated, metastatic HER2-positive breast cancer was improved compared with physician’s choice chemotherapy.

Improved survival outcomes were reported with the addition of nivolumab to either ipilimumab or chemo-therapy vs chemotherapy alone in the frontline treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.

The frequency of neurologic toxicities from ciltacabtagene autoleucel can be reduced with management strategies for patients with relapsed or refractory multiple myeloma treated with the chimeric antigen receptor T-cell therapy, findings from CARTITUDE-2 show.

In patients with relapsed/refractory multiple myeloma, treatment with higher doses of subcutaneous elranatamab was found to be effective, according to findings from a phase 1 clinical trial.

In select previously treated patients with chronic lymphocytic leukemia, treatment with acalabrutinib was found to be noninferior but better tolerated compared with ibrutinib.

Promising responses and disease control rates were observed with larotrectinib administered as treatment of patients with TRK fusion-positive central nervous system tumors.

Response rates in patients with metastatic urothelial carcinoma were boosted when the novel PI3K-y inhibitor eganelisib was added to nivolumab, according to recent research presented during the American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium.

A correlation between the emergence of immune-related adverse events and presence of mutations was identified in patients with non-small lung cancer receiving immunotherapy.

Patients with epithelial ovarian cancer treated with weekly dose-dense chemotherapy in the ICON8 clinical trial experienced similar progression-free survival and overall survival as patients treated with the standard-of-care.

Another treatment option would be a welcome change for these patients, who tend to have poor prognoses once they run out of treatment options, according to Saad Z. Usmani, MD. After becoming refractory to available therapies, median overall survival is 6-11 months.

"The totality of data from the two trials presented at ASCO suggests that zanubrutinib may be a preferred treatment option for patients with WM, regardless of whether they have received prior treatment."

Comparable efficacy and minimized adverse events were seen with a lower dose of oxaliplatin (Eloxatin) and capecitabine (Xeloda) in elderly and frail patients with advanced gastroesophageal cancer, according to findings to be presented during the 2019 American Society of Clinical Oncology Annual Meeting.

The majority of younger patients ultimately diagnosed with colorectal cancer waited 3 to 12 months to see a doctor after symptoms began and were commonly misdiagnosed with issues such as hemorrhoids, irritable bowel syndrome, and anemia, according to recent findings.

A telephone-based lifestyle intervention program led to weight loss and higher rates of disease-free survival in early-stage breast cancer survivors, according to findings of a recent study.